Table 2.
Association between Clinicopathologic factors, including IMP3 expression, and Relapse Free Survival
| Parameter | Number of patients | Survival (months) Median ± SE | 95% confidence interval | P value (univariate) | P value (multivariate) |
|---|---|---|---|---|---|
| IMP3 composite score | |||||
| 0-100 (negative-mildly positive) | 12 | 75.6 ± 7 | 61.8 – 89.4 | 0.09 | NS |
| 101-200 (moderately positive) | 17 | 81.3 ± 11.7 | 58.4 – 104.5 | ||
| >200 (strongly positive) | 14 | 48.4 ± 13.5 | 22.1- 74.9 | ||
| Age | |||||
| > 65 years | 25 | 70.6 ± 9.3 | 52.2 – 88.8 | 0.02 | 0.023 |
| ≤ 65 years | 18 | 75.6 ± 10.7 | 54.7 – 96.5 | ||
| FIGO stage | |||||
| 1 and II | 26 | 91.2 ± 7.1 | 77.3 – 104.8 | 0.002 | NS |
| III and IV | 17 | 16.5 ± 2.0 | 12.5 – 20.5 | ||
| Architectural pattern In >50% of tumor | |||||
| Glandular | 17 | 71.8 ± 10.5 | 51.2 – 92.5 | NS | NS |
| papillary | 12 | 64.4 ± 15.8 | 33.3 – 95.4 | ||
| Solid | 10 | 37.4 ± 3.4 | 30.5 – 44.1 | ||
| cystic | 4 | 60.3 ± 18.5 | 24.1 – 96.6 | ||
| Lymph nodes | |||||
| positive | 8 | 13.7 ± 2.8 | 8.2 - 19.1 | 0.002 | NS |
| negative | 29 | 84.1± 8.1 | 96.1- 101.4 | ||
| Lymphovascular Invasion | |||||
| positive | 20 | 70.1 ± 11.1 | 48.4- 91.8 | NS | NS |
| negative | 22 | 76.4 ± 8.9 | 58.9-93.9 | ||
| Myometrium invasion | |||||
| >50% | 19 | 57.2 ± 9.3 | 38.1 – 76.4 | NS | NS |
| ≤50% | 24 | 81.3 ± 10.4 | 62.7 – 98.5 | ||
| Unknown | 1 | ||||
| Mitotic index | |||||
| >4 | 12 | 68.9 ± 13.4 | 42.7 – 95.2 | NS | NS |
| ≤4 | 31 | 77.3 ± 7.6 | 61.3 – 91.2 | ||
| Architectural gradea | |||||
| A+B | 24 | 77.1 ± 9.4 | 58.6 – 95.5 | 0.09 | NS |
| C | 19 | 32.6 ± 3.6 | 25.6 – 39.6 | ||
NS: not statistically significant (all p values between 0.05 and 0.09999 are listed); SE standard error; FIGO international Federation of Gynecology and Obstetrics.
a
Architectural grade per Yamamoto et al criteria (10)